Stay Updated: Posts | Comments

  • 30th May 2010 - By Joel Lord

    Meningitis bacteriaA substantial new Bill to require meningitis vaccine for 7th graders and ALL college students is gaining momentum in Albany, New York
    http://www.healthfreedomusa.org/?p=5472

    Bill S7156 passed the Senate Health Committee and is due for a floor vote.

    Bill A10313 will be voted on the Assembly Health Committee any given Tuesday.
    http://www.ncsl.org/IssuesResearch/Health/
    MeningitisLegislationandLaws/tabid/13960/Default.aspx

    Assuming this Bill is rammed through the Senate & Health Committee which seems inevitable the public must be alerted immediately to the serious risks associated with this vaccine. If New York buckles under pressure then other States & countries around the world are sure to follow. There are 3 Meningitis Vaccines being promoted by the WHO & CDC for distribution in this campaign including:

    1) MENACTRA (Manufactured by Sanofi Pasteur Inc.)

    Menactra-300x300Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (1) and grown in Watson Scherp(2) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration. To prepare the polysaccharides for conjugation, they are depolymerized, derivatized, and purified by diafiltration. Corynebacterium diphtheriae cultures are grown in a modified Mueller and Miller medium (3) and detoxified with formaldehyde. The diphtheria toxoid protein is purified by ammonium sulfate fractionation and diafiltration.
    http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf

    Package Insert: General Warnings –

    NURSING MOTHERS: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Menactra vaccine is administered to a nursing woman.

    PEDIATRIC USE: Safety and effectiveness of Menactra vaccine in children below the age of 2 years have not been established.

    GERIATRIC USE: Safety and effectiveness of Menactra vaccine in adults older than 55 years have not been established

    CARCINOGENESIS, MUTAGENESIS – IMPAIRMENT OF FERTILITY: Menactra vaccine has not been evaluated in animals for its carcinogenic or mutagenic potentials or for impairment of fertility.

    CONTRAINDICATIONS: Known hypersensitivity to any component of Menactra vaccine including diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components, are contraindications to vaccine administration.

    GUILLAIN-BARRE SYNDROME: Guillain-Barré syndrome has been reported in temporal relationship following administration of Menactra vaccine. An evaluation of post-marketing adverse events suggests a potential for an increased risk of GBS following Menactra vaccination. Persons previously diagnosed with GBS should not receive Menactra vaccine.

    LATEX: The stopper of the vial contains dry natural rubber latex, which may cause allergic reactions in latex-sensitive individuals. There is no latex in any component of the syringe.

    2) MENOMUNE (Manufactured by Sanofi Pasteur Inc.)

    Sanofi_Pasteur-logo-1E51D9C735-seeklogo.comMenomune® – A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated with Mueller Hinton agar1 and Watson Scherp2 media. The purified polysaccharide is extracted from the Neisseria meningitidis cells and separated from the media by procedures which include centrifugation, detergent precipitation, alcohol precipitation, solvent or organic extraction and diafiltration.
    http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131653.pdf

    Package Insert: General Warnings –

    IT IS A CONTRAINDICATION TO ADMINISTER MENOMUNE – A/C/Y/W-135 VACCINE TO INDIVIDUALS KNOWN TO BE SENSITIVE TO THIMEROSAL OR ANY OTHER COMPONENT OF THE VACCINE.

    FOR INDIVIDUALS SENSITIVE TO THIMEROSAL, ADMINISTER THE ONE DOSE PACKAGE SIZE AND RECONSTITUTE WITH THE 0.78 ML VIAL OF DILUENT THAT CONTAINS NO PRESERVATIVE.

    WARNING: This product contains dry natural latex rubber as follows: The stopper to the vial contains dry natural latex rubber.

    If the vaccine is used in persons receiving immunosuppressive therapy, the expected immune response may not be obtained.

    VACCINE INTERACTIONS – Menomune should NOT be given at the same time as whole-cell pertussis or whole-cell typhoid vaccines due to combined endotoxin content.20,21

    PRECAUTIONS: EPINEPHRINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE TO COMBAT UNEXPECTED ANAPHYLACTIC OR OTHER ALLERGIC REACTIONS.

    DRUG INTERACTIONS: If Menomune – A/C/Y/W-135 vaccine is administered to immunosuppressed persons or persons receiving immunosuppressive
    therapy, an adequate immunologic response may not be obtained.

    CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Menomune – A/C/Y/W-135 vaccine has not been evaluated in animals for its carcinogenic, mutagenic potentials or impairment
    of fertility.

    PREGNANCY CATEGORY C: Animal reproduction studies have not been conducted with Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135. It is also not known whether Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Meningococcal Polysaccharide Vaccine, Groups A, C, Y
    and W-135 should be given to a pregnant woman only if clearly needed.

    NURSING MOTHERS: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Menomune – A/C/Y/W-135 vaccine is administered to a nursing woman.

    PEDIATRIC USE SAFETY AND EFFECTIVENESS OF MENOMUNE – A/C/Y/W-135 VACCINE IN CHILDREN BELOW THE AGE OF 2 YEARS HAVE NOT BEEN ESTABLISHED.

    3) MENVEO (Manufatured by Novartis Vaccines and Diagnostics, Inc.)

    menveoMenveo® [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] is a sterile liquid vaccine administered by intramuscular injection that contains N. meningitidis serogroup A, C, Y and W-135 oligosaccharides conjugated individually to Corynebacterium diphtheriae CRM197 protein. The polysaccharides are produced by bacterial fermentation of N. meningitidis (serogroups A, C, Y or W-135). N. meningitidis strains A, C, Y and W-135 are each cultured and grown on Franz Complete medium and treated with formaldehyde. MenA, MenW-135 and MenY polysaccharides are purified by several extraction and precipitation steps. MenC polysaccharide is purified by a combination of chromatography and precipitation steps.
    The protein carrier (CRM197) is produced by bacterial fermentation and is purified by a series of chromatography and ultrafiltration steps. C. diphtheriae is cultured and grown on CY medium containing yeast extracts and amino acids.
    http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf

    *NOTE: C. diphtheriae is cultured and grown on CY medium containing yeast extracts refers to genetically modified yeast. Anyone with an allergy to gluten will be adversely affected by this process.

    Package Insert: General Warnings –

    PRECAUTIONS: Management of Acute Allergic Reactions Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO.

    SYNCOPE: Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with MENVEO. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position.

    Altered Immunocompetence Safety and effectiveness of MENVEO have not been evaluated in immunocompromised persons. If MENVEO is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.

    GUILLAIN-BARRE SYNDROME: Following vaccination with a U.S.-licensed meningococcal quadrivalent polysaccharide conjugate vaccine, an evaluation of post-marketing adverse events suggested a potential for an increased risk of Guillain-Barré Syndrome (GBS). Data are not available to evaluate the potential risk of GBS following administration of MENVEO.

    BLEEDING DISORDERS: MENVEO should not be administered to persons with any bleeding disorder, or persons receiving anticoagulant therapy, unless the potential benefit outweighs the risk of administration.

    Complete list of Meningitis Vaccines Found Here
    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093830.htm

    MENINGITIS: THE FACTS  – These days, when a vaccinee develops poliomyelitis, it may not be called poliomyelitis; instead, it may be called viral or aseptic meningitis, ascending paralysis (Guillain-Barre syndrome), cerebral palsy (over 75 per cent of cases are not diagnosed at birth but after six months) or other such names. According to MMWR (1997; 32[29]:384-385), there are 30,000 to 50,000 cases of aseptic meningitis every year in the United States. Considering that the vast majority (99 per cent) of the reported cases in the pre-vaccine era were non-paralytic and would have corresponded to aseptic or aviral meningitis, then vaccination has actually increased the incidence of poliomyelitis. In the pre-vaccine era, such high numbers only occurred in some epidemics. Now, such numbers occur every year, year by year.
    http://www.whale.to/vaccines/meningitis2.htm

    The Department of Health has refused to carry out a review into the safety of the meningitis C vaccine despite fears it is unsafe. New figures show that almost 5,000 children have suffered adverse reactions to the vaccine since it was introduced. The Chiron jab was introduced in June of 2000, a year ahead of schedule, as a protection against the meningitis C strain. It has been given to 13m children and university students across the UK. But according to figures from the Medical Controls Agency there were 4,764 reports of adverse reactions to the vaccine up to the beginning of June. A further 10,202 suspected reactions have been reported while an investigation has been launched into the deaths of eight children to see if there is a link to the vaccine.
    http://www.nccn.net/~wwithin/meningitisc.htm

    Autism Action Network bannerGRASSROOTS COMMUNITY ORGANIZING TO COUNTER LEGISLATION: Stop Stealth Mandatory Meningitis Vaccine Bill In New York. Come to Albany on Tuesday, June 1
    http://capwiz.com/a-champ/issues/alert/?alertid=15089571

    Related Articles:

    VRM Worldwide Autism Study
    http://vaccineresistancemovement.org/?page_id=5463

    VRM: The Problem With Vaccines Part 1
    http://vaccineresistancemovement.org/?p=488

    VRM: The Problem With Vaccines Part 2 – Synergistic Effect of Heavy Metal Toxicity On The Body
    http://vaccineresistancemovement.org/?p=6097

    VRM: Vaccine Clinic – A Concise Compendium To The Problem With Vaccines
    http://vaccineresistancemovement.org/?p=6278

    VRM: The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
    http://vaccineresistancemovement.org/?p=6880

    VRM: A Concise Compendium To The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
    http://vaccineresistancemovement.org/?p=7283

    VRM: The Problem With Vaccines Part 4 – Primary Aspects of Vaccine Toxicity Affecting Body
    http://vaccineresistancemovement.org/?p=8787

    VRM: The Problem With Vaccines Part 5A – Detoxification & Restoration of the Body
    http://vaccineresistancemovement.org/?p=8836

    VRM: The Problem With Vaccines Part 5B – Detoxification & Restoration of the Body
    http://vaccineresistancemovement.org/?p=8847

    VRM: Vaccine Ingredients
    http://vaccineresistancemovement.org/?p=979

    VRM: Family Charts Gradual Decline Of Daughter
    http://vaccineresistancemovement.org/?p=3156

    VRM: Autism – Steps To Take Toward Prevention
    http://vaccineresistancemovement.org/?p=3028

    VRM: Health Matters Part 1
    http://vaccineresistancemovement.org/?p=6719

    VRM: Health Matters Part 2
    http://vaccineresistancemovement.org/?p=6746%EF%BB%BF

    VRM: Alternative Cancer Cures That Work
    http://vaccineresistancemovement.org/?p=3729

    VRM: Pregnancy Tips
    http://vaccineresistancemovement.org/?p=3270

    VRM: The Vanishing Sperm Count
    http://vaccineresistancemovement.org/?p=4639

    VRM: Media Spin & Swine Flu Hysteria
    http://vaccineresistancemovement.org/?p=2347

    VRM: H1N1 Vaccine Surplus From 2009 Reveals Growing Distrust of Gov’t & WHO – Cost To Taxpayers Exceeds 2.5 Billion
    http://vaccineresistancemovement.org/?p=4969

    VRM: Flu Death Statistics – WHO & The Big Lie
    http://vaccineresistancemovement.org/?p=784

    VRM: Canada’s 2010-11 Flu Vaccine A Deadly Concoction
    http://vaccineresistancemovement.org/?p=5692

    VRM: United States 2010-11 Flu Vaccine Afluria – Buyer Beware
    http://vaccineresistancemovement.org/?p=5271

    VRM: Australian Vaccine Scandal
    http://vaccineresistancemovement.org/?p=3377

    VRM: Polio – United Nations & The Great Cull
    http://vaccineresistancemovement.org/?p=4916

    VRM : Vaccine Industry Deception, Propaganda & Media Collusion
    http://vaccineresistancemovement.org/?p=197

    VRM: Birth of Medical & Scientific Dictatorship – Future Scenarios
    http://vaccineresistancemovement.org/?p=997

    VRM: H1N1 Bio-weaponry Incorporated
    http://vaccineresistancemovement.org/?p=884

    VRM : Aids & The WHO Connection – Criminal Intent
    http://vaccineresistancemovement.org/?p=1749

    VRM: Morgellons Syndrome & Chemtrails
    http://vaccineresistancemovement.org/?p=839

    VRM : Council On Foreign Relations 10/16/09- Major Influence on Government Vaccine Policy
    http://vaccineresistancemovement.org/?p=1880

    VRM: Closed Door CDC Meeting Reveals Industry Cover-up Of Heavy Metal Toxicity In Vaccines
    http://vaccineresistancemovement.org/?p=5935

    VRM: The Rockefeller Foundation Drafts A Post-Pandemic Scenario
    http://vaccineresistancemovement.org/?p=5102

    VRM : World Health Organization & Vaccine Manufacturers Implicated In Massive H1N1 Financial Scam Involving Kickbacks & Cover-ups
    http://vaccineresistancemovement.org/?p=4610

    VRM : Former Pharmaceutical Representative Gwen Olsen Exposes Systemic Industry Fraud
    http://vaccineresistancemovement.org/?p=5920

    VRM: Britain’s National Health Service – Criminal Syndicate Swindling Billions While Rapidly Destroying Health Care System
    http://vaccineresistancemovement.org/?p=4986

    VRM: UK Institutes Brand of Medical Martial Law With ‘Super-Vaccination’ Day
    http://vaccineresistancemovement.org/?p=4986

    VRM : The Awakening Has Begun
    http://vaccineresistancemovement.org/?p=6469

    VRM: Medical Martial Law In The US – Sleeping Giant Of Tyranny
    http://vaccineresistancemovement.org/?p=5865

    VRM : Multi-Virus Vaccine Quinvaxem Proving Deadly
    http://vaccineresistancemovement.org/?p=5219

    VRM: New Generation Cancer Vaccine Will Cause Infertility
    http://vaccineresistancemovement.org/?p=5311

    VRM: CDC-Gate Exposes A Trail of Fraud Behind Autism Studies
    http://vaccineresistancemovement.org/?p=5743

    VRM : Squaline – The Military Agenda Comes Home
    http://vaccineresistancemovement.org/?p=1797

    VRM Live – 01/28/11: Vaccine Resistance Movement founder Joel Lord discusses Synthetic Genomics, cloned cell vaccine technology & the death of natural immunity, gutter journalism & Dr. Wakefield’s imminent vindication with ‘Truth to Power’ host Paul Mabelis.
    http://www.blogtalkradio.com/empradio/2011/01/28/truth-to-power-thursday

    VRM Live – 11/04/10: Vaccine Resistance Movement founder Joel Lord lays out the whole vaccine process with Paul Mabelis; including heavy metal toxicity, synergy, pregnancy issues & the basic principles of natural health at risk.
    http://www.blogtalkradio.com/show.aspx?userurl=empradio&year=2010&month=11&day=05&url=truth-to-power-thursday

    VRM Live – 09/24/10: Vaccine Resistance Movement Founder Joel Lord & activist/radio host Jesse Calhoun lay it all out tonite. Topics include the VRM Worldwide Autism Study, Scientific/Medical dictatorship, Natural Rights & Vaccine Industry fraud exposed. Special thanks to host Paul Mabelis.
    http://www.blogtalkradio.com/empradio/2010/09/24/truth-to-power-thursday

    If you appreciate the efforts to bring this information forward do consider making a donation. Any amount, no matter how small will help enable me to carry on this invaluable research. See Paypal link on the VRM website (click on ‘Donate’ tab in upper right corner). Thank you all.

    logo.VRM_Ver.2.1

  • Leave a Reply

    You must be logged in to post a comment.


<ul><li><strong>woo_ad_footer</strong> - false</li><li><strong>woo_ad_footer_adsense</strong> - </li><li><strong>woo_ad_footer_image</strong> - http://vaccineresistancemovement.org/wp-content/woo_uploads/4-3-banner-oxysilver.jpg</li><li><strong>woo_ad_footer_url</strong> - </li><li><strong>woo_alt_stylesheet</strong> - default.css</li><li><strong>woo_auto_img</strong> - false</li><li><strong>woo_cat_color_1</strong> - </li><li><strong>woo_cat_color_10</strong> - </li><li><strong>woo_cat_color_100</strong> - </li><li><strong>woo_cat_color_101</strong> - </li><li><strong>woo_cat_color_102</strong> - </li><li><strong>woo_cat_color_103</strong> - </li><li><strong>woo_cat_color_104</strong> - </li><li><strong>woo_cat_color_105</strong> - </li><li><strong>woo_cat_color_106</strong> - </li><li><strong>woo_cat_color_107</strong> - </li><li><strong>woo_cat_color_109</strong> - </li><li><strong>woo_cat_color_11</strong> - </li><li><strong>woo_cat_color_12</strong> - </li><li><strong>woo_cat_color_126</strong> - </li><li><strong>woo_cat_color_127</strong> - </li><li><strong>woo_cat_color_13</strong> - </li><li><strong>woo_cat_color_131</strong> - </li><li><strong>woo_cat_color_135</strong> - </li><li><strong>woo_cat_color_136</strong> - </li><li><strong>woo_cat_color_137</strong> - </li><li><strong>woo_cat_color_138</strong> - </li><li><strong>woo_cat_color_14</strong> - </li><li><strong>woo_cat_color_141</strong> - </li><li><strong>woo_cat_color_142</strong> - </li><li><strong>woo_cat_color_144</strong> - </li><li><strong>woo_cat_color_15</strong> - </li><li><strong>woo_cat_color_16</strong> - </li><li><strong>woo_cat_color_160</strong> - </li><li><strong>woo_cat_color_162</strong> - </li><li><strong>woo_cat_color_165</strong> - </li><li><strong>woo_cat_color_169</strong> - </li><li><strong>woo_cat_color_17</strong> - </li><li><strong>woo_cat_color_171</strong> - </li><li><strong>woo_cat_color_172</strong> - </li><li><strong>woo_cat_color_173</strong> - </li><li><strong>woo_cat_color_174</strong> - </li><li><strong>woo_cat_color_175</strong> - </li><li><strong>woo_cat_color_176</strong> - </li><li><strong>woo_cat_color_177</strong> - </li><li><strong>woo_cat_color_178</strong> - </li><li><strong>woo_cat_color_18</strong> - </li><li><strong>woo_cat_color_19</strong> - </li><li><strong>woo_cat_color_20</strong> - </li><li><strong>woo_cat_color_21</strong> - </li><li><strong>woo_cat_color_22</strong> - </li><li><strong>woo_cat_color_23</strong> - </li><li><strong>woo_cat_color_24</strong> - </li><li><strong>woo_cat_color_25</strong> - </li><li><strong>woo_cat_color_26</strong> - </li><li><strong>woo_cat_color_27</strong> - </li><li><strong>woo_cat_color_28</strong> - 03246B</li><li><strong>woo_cat_color_29</strong> - </li><li><strong>woo_cat_color_3</strong> - </li><li><strong>woo_cat_color_30</strong> - </li><li><strong>woo_cat_color_31</strong> - </li><li><strong>woo_cat_color_32</strong> - </li><li><strong>woo_cat_color_35</strong> - </li><li><strong>woo_cat_color_37</strong> - </li><li><strong>woo_cat_color_38</strong> - </li><li><strong>woo_cat_color_39</strong> - </li><li><strong>woo_cat_color_4</strong> - </li><li><strong>woo_cat_color_40</strong> - </li><li><strong>woo_cat_color_41</strong> - </li><li><strong>woo_cat_color_42</strong> - </li><li><strong>woo_cat_color_46</strong> - </li><li><strong>woo_cat_color_49</strong> - </li><li><strong>woo_cat_color_5</strong> - </li><li><strong>woo_cat_color_50</strong> - </li><li><strong>woo_cat_color_51</strong> - </li><li><strong>woo_cat_color_52</strong> - </li><li><strong>woo_cat_color_53</strong> - </li><li><strong>woo_cat_color_54</strong> - </li><li><strong>woo_cat_color_55</strong> - </li><li><strong>woo_cat_color_56</strong> - </li><li><strong>woo_cat_color_57</strong> - </li><li><strong>woo_cat_color_58</strong> - </li><li><strong>woo_cat_color_59</strong> - </li><li><strong>woo_cat_color_6</strong> - </li><li><strong>woo_cat_color_60</strong> - </li><li><strong>woo_cat_color_61</strong> - </li><li><strong>woo_cat_color_62</strong> - </li><li><strong>woo_cat_color_63</strong> - </li><li><strong>woo_cat_color_64</strong> - </li><li><strong>woo_cat_color_65</strong> - </li><li><strong>woo_cat_color_66</strong> - </li><li><strong>woo_cat_color_67</strong> - </li><li><strong>woo_cat_color_68</strong> - </li><li><strong>woo_cat_color_69</strong> - </li><li><strong>woo_cat_color_7</strong> - </li><li><strong>woo_cat_color_70</strong> - </li><li><strong>woo_cat_color_71</strong> - </li><li><strong>woo_cat_color_72</strong> - </li><li><strong>woo_cat_color_73</strong> - </li><li><strong>woo_cat_color_74</strong> - </li><li><strong>woo_cat_color_75</strong> - </li><li><strong>woo_cat_color_76</strong> - </li><li><strong>woo_cat_color_77</strong> - </li><li><strong>woo_cat_color_78</strong> - </li><li><strong>woo_cat_color_79</strong> - 2F83DE</li><li><strong>woo_cat_color_8</strong> - </li><li><strong>woo_cat_color_80</strong> - </li><li><strong>woo_cat_color_81</strong> - </li><li><strong>woo_cat_color_82</strong> - </li><li><strong>woo_cat_color_83</strong> - </li><li><strong>woo_cat_color_84</strong> - </li><li><strong>woo_cat_color_85</strong> - </li><li><strong>woo_cat_color_86</strong> - </li><li><strong>woo_cat_color_87</strong> - </li><li><strong>woo_cat_color_88</strong> - </li><li><strong>woo_cat_color_89</strong> - </li><li><strong>woo_cat_color_9</strong> - </li><li><strong>woo_cat_color_90</strong> - </li><li><strong>woo_cat_color_91</strong> - </li><li><strong>woo_cat_color_92</strong> - </li><li><strong>woo_cat_color_93</strong> - </li><li><strong>woo_cat_color_94</strong> - </li><li><strong>woo_cat_color_95</strong> - </li><li><strong>woo_cat_color_96</strong> - </li><li><strong>woo_cat_color_97</strong> - </li><li><strong>woo_cat_color_98</strong> - </li><li><strong>woo_cat_color_99</strong> - </li><li><strong>woo_cat_nav_1</strong> - true</li><li><strong>woo_cat_nav_10</strong> - true</li><li><strong>woo_cat_nav_100</strong> - false</li><li><strong>woo_cat_nav_101</strong> - true</li><li><strong>woo_cat_nav_102</strong> - true</li><li><strong>woo_cat_nav_103</strong> - true</li><li><strong>woo_cat_nav_104</strong> - true</li><li><strong>woo_cat_nav_105</strong> - true</li><li><strong>woo_cat_nav_106</strong> - false</li><li><strong>woo_cat_nav_107</strong> - false</li><li><strong>woo_cat_nav_109</strong> - false</li><li><strong>woo_cat_nav_11</strong> - true</li><li><strong>woo_cat_nav_12</strong> - true</li><li><strong>woo_cat_nav_126</strong> - false</li><li><strong>woo_cat_nav_127</strong> - false</li><li><strong>woo_cat_nav_13</strong> - true</li><li><strong>woo_cat_nav_131</strong> - false</li><li><strong>woo_cat_nav_135</strong> - false</li><li><strong>woo_cat_nav_136</strong> - false</li><li><strong>woo_cat_nav_137</strong> - false</li><li><strong>woo_cat_nav_138</strong> - false</li><li><strong>woo_cat_nav_14</strong> - true</li><li><strong>woo_cat_nav_141</strong> - false</li><li><strong>woo_cat_nav_142</strong> - false</li><li><strong>woo_cat_nav_144</strong> - false</li><li><strong>woo_cat_nav_15</strong> - true</li><li><strong>woo_cat_nav_16</strong> - false</li><li><strong>woo_cat_nav_160</strong> - false</li><li><strong>woo_cat_nav_162</strong> - false</li><li><strong>woo_cat_nav_165</strong> - false</li><li><strong>woo_cat_nav_169</strong> - false</li><li><strong>woo_cat_nav_17</strong> - true</li><li><strong>woo_cat_nav_171</strong> - false</li><li><strong>woo_cat_nav_172</strong> - false</li><li><strong>woo_cat_nav_173</strong> - false</li><li><strong>woo_cat_nav_174</strong> - false</li><li><strong>woo_cat_nav_175</strong> - false</li><li><strong>woo_cat_nav_176</strong> - false</li><li><strong>woo_cat_nav_177</strong> - false</li><li><strong>woo_cat_nav_178</strong> - false</li><li><strong>woo_cat_nav_18</strong> - true</li><li><strong>woo_cat_nav_19</strong> - true</li><li><strong>woo_cat_nav_20</strong> - false</li><li><strong>woo_cat_nav_21</strong> - true</li><li><strong>woo_cat_nav_22</strong> - true</li><li><strong>woo_cat_nav_23</strong> - true</li><li><strong>woo_cat_nav_24</strong> - false</li><li><strong>woo_cat_nav_25</strong> - true</li><li><strong>woo_cat_nav_26</strong> - true</li><li><strong>woo_cat_nav_27</strong> - true</li><li><strong>woo_cat_nav_28</strong> - false</li><li><strong>woo_cat_nav_29</strong> - true</li><li><strong>woo_cat_nav_3</strong> - true</li><li><strong>woo_cat_nav_30</strong> - true</li><li><strong>woo_cat_nav_31</strong> - true</li><li><strong>woo_cat_nav_32</strong> - true</li><li><strong>woo_cat_nav_35</strong> - true</li><li><strong>woo_cat_nav_37</strong> - true</li><li><strong>woo_cat_nav_38</strong> - true</li><li><strong>woo_cat_nav_39</strong> - true</li><li><strong>woo_cat_nav_4</strong> - false</li><li><strong>woo_cat_nav_40</strong> - true</li><li><strong>woo_cat_nav_41</strong> - true</li><li><strong>woo_cat_nav_42</strong> - true</li><li><strong>woo_cat_nav_46</strong> - false</li><li><strong>woo_cat_nav_49</strong> - true</li><li><strong>woo_cat_nav_5</strong> - true</li><li><strong>woo_cat_nav_50</strong> - false</li><li><strong>woo_cat_nav_51</strong> - true</li><li><strong>woo_cat_nav_52</strong> - true</li><li><strong>woo_cat_nav_53</strong> - true</li><li><strong>woo_cat_nav_54</strong> - true</li><li><strong>woo_cat_nav_55</strong> - true</li><li><strong>woo_cat_nav_56</strong> - true</li><li><strong>woo_cat_nav_57</strong> - true</li><li><strong>woo_cat_nav_58</strong> - false</li><li><strong>woo_cat_nav_59</strong> - true</li><li><strong>woo_cat_nav_6</strong> - true</li><li><strong>woo_cat_nav_60</strong> - false</li><li><strong>woo_cat_nav_61</strong> - true</li><li><strong>woo_cat_nav_62</strong> - true</li><li><strong>woo_cat_nav_63</strong> - false</li><li><strong>woo_cat_nav_64</strong> - true</li><li><strong>woo_cat_nav_65</strong> - true</li><li><strong>woo_cat_nav_66</strong> - false</li><li><strong>woo_cat_nav_67</strong> - true</li><li><strong>woo_cat_nav_68</strong> - false</li><li><strong>woo_cat_nav_69</strong> - true</li><li><strong>woo_cat_nav_7</strong> - true</li><li><strong>woo_cat_nav_70</strong> - true</li><li><strong>woo_cat_nav_71</strong> - true</li><li><strong>woo_cat_nav_72</strong> - true</li><li><strong>woo_cat_nav_73</strong> - true</li><li><strong>woo_cat_nav_74</strong> - true</li><li><strong>woo_cat_nav_75</strong> - true</li><li><strong>woo_cat_nav_76</strong> - true</li><li><strong>woo_cat_nav_77</strong> - true</li><li><strong>woo_cat_nav_78</strong> - true</li><li><strong>woo_cat_nav_79</strong> - true</li><li><strong>woo_cat_nav_8</strong> - true</li><li><strong>woo_cat_nav_80</strong> - true</li><li><strong>woo_cat_nav_81</strong> - true</li><li><strong>woo_cat_nav_82</strong> - true</li><li><strong>woo_cat_nav_83</strong> - true</li><li><strong>woo_cat_nav_84</strong> - false</li><li><strong>woo_cat_nav_85</strong> - true</li><li><strong>woo_cat_nav_86</strong> - true</li><li><strong>woo_cat_nav_87</strong> - true</li><li><strong>woo_cat_nav_88</strong> - true</li><li><strong>woo_cat_nav_89</strong> - true</li><li><strong>woo_cat_nav_9</strong> - true</li><li><strong>woo_cat_nav_90</strong> - true</li><li><strong>woo_cat_nav_91</strong> - true</li><li><strong>woo_cat_nav_92</strong> - true</li><li><strong>woo_cat_nav_93</strong> - true</li><li><strong>woo_cat_nav_94</strong> - true</li><li><strong>woo_cat_nav_95</strong> - true</li><li><strong>woo_cat_nav_96</strong> - true</li><li><strong>woo_cat_nav_97</strong> - true</li><li><strong>woo_cat_nav_98</strong> - true</li><li><strong>woo_cat_nav_99</strong> - true</li><li><strong>woo_custom_css</strong> - </li><li><strong>woo_custom_favicon</strong> - </li><li><strong>woo_feedburner_url</strong> - </li><li><strong>woo_google_analytics</strong> - <script type=\"text/javascript\">
var gaJsHost = ((\"https:\" == document.location.protocol) ? \"https://ssl.\" : \"http://www.\");
document.write(unescape(\"%3Cscript src=\'\" + gaJsHost + \"google-analytics.com/ga.js\' type=\'text/javascript\'%3E%3C/script%3E\"));
</script>
<script type=\"text/javascript\">
try {
var pageTracker = _gat._getTracker(\"UA-13204227-1\");
pageTracker._trackPageview();
} catch(err) {}</script></li><li><strong>woo_logo</strong> - </li><li><strong>woo_manual</strong> - http://www.woothemes.com/support/theme-documentation/wootheme/</li><li><strong>woo_post_size</strong> - false</li><li><strong>woo_resize</strong> - false</li><li><strong>woo_shortname</strong> - woo</li><li><strong>woo_sidebar_ad_href_1</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_href_2</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_href_3</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_href_4</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_1</strong> - http://www.woothemes.com/ads/woothemes-125x125-1.gif</li><li><strong>woo_sidebar_ad_img_2</strong> - http://www.woothemes.com/ads/woothemes-125x125-2.gif</li><li><strong>woo_sidebar_ad_img_3</strong> - http://www.woothemes.com/ads/woothemes-125x125-3.gif</li><li><strong>woo_sidebar_ad_img_4</strong> - http://www.woothemes.com/ads/woothemes-125x125-4.gif</li><li><strong>woo_single_thumb</strong> - true</li><li><strong>woo_themename</strong> - myweblog</li><li><strong>woo_uploads</strong> - a:2:{i:0;s:84:"http://vaccineresistancemovement.org/wp-content/woo_uploads/4-3-banner-oxysilver.jpg";i:1;s:82:"http://vaccineresistancemovement.org/wp-content/woo_uploads/3-banner-oxysilver.jpg";}</li></ul>